Evofem Biosciences (EVFM) Competitors

$0.0074 0.00 (0.00%)

As of 05/22/2026 03:52 PM Eastern

EVFM vs. INDP, GOVX, SNGX, AKTX, and IOBT

Should you buy Evofem Biosciences stock or one of its competitors? MarketBeat compares Evofem Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evofem Biosciences include Indaptus Therapeutics (INDP), GeoVax Labs (GOVX), Soligenix (SNGX), Akari Therapeutics (AKTX), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical products" industry.

How does Evofem Biosciences compare to Indaptus Therapeutics?

Evofem Biosciences (NASDAQ:EVFM) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Evofem Biosciences has a beta of -1.32, indicating that its stock price is 232% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

In the previous week, Evofem Biosciences' average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score.

Company	Overall Sentiment
Evofem Biosciences	Neutral
Indaptus Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Evofem Biosciences has higher revenue and earnings than Indaptus Therapeutics. Evofem Biosciences is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.07	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

Indaptus Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 0.0% of Evofem Biosciences shares are owned by company insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Evofem Biosciences beats Indaptus Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Evofem Biosciences compare to GeoVax Labs?

Evofem Biosciences (NASDAQ:EVFM) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Evofem Biosciences has a beta of -1.32, suggesting that its share price is 232% less volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.36, suggesting that its share price is 236% more volatile than the broader market.

Evofem Biosciences has higher revenue and earnings than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.07	N/A
GeoVax Labs	$2.49M	5.07	-$21.47M	-$19.12	N/A

GeoVax Labs has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
GeoVax Labs	N/A	-709.52%	-399.33%

GeoVax Labs has a consensus price target of $150.00, suggesting a potential upside of 4,020.88%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Evofem Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 0.0% of Evofem Biosciences shares are owned by company insiders. Comparatively, 0.6% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, GeoVax Labs had 6 more articles in the media than Evofem Biosciences. MarketBeat recorded 6 mentions for GeoVax Labs and 0 mentions for Evofem Biosciences. GeoVax Labs' average media sentiment score of 0.59 beat Evofem Biosciences' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Evofem Biosciences	Neutral
GeoVax Labs	Positive

Summary

GeoVax Labs beats Evofem Biosciences on 9 of the 15 factors compared between the two stocks.

How does Evofem Biosciences compare to Soligenix?

Soligenix (NASDAQ:SNGX) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Soligenix has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.32, meaning that its stock price is 232% less volatile than the broader market.

In the previous week, Soligenix had 6 more articles in the media than Evofem Biosciences. MarketBeat recorded 6 mentions for Soligenix and 0 mentions for Evofem Biosciences. Soligenix's average media sentiment score of 1.00 beat Evofem Biosciences' score of 0.00 indicating that Soligenix is being referred to more favorably in the media.

Company	Overall Sentiment
Soligenix	Positive
Evofem Biosciences	Neutral

3.6% of Soligenix shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 3.1% of Soligenix shares are held by insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Soligenix presently has a consensus price target of $6.00, suggesting a potential upside of 1,438.07%. Given Soligenix's stronger consensus rating and higher possible upside, equities analysts clearly believe Soligenix is more favorable than Evofem Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Evofem Biosciences has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	48.18	-$11.08M	-$1.68	N/A
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.07	N/A

Soligenix has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Summary

Soligenix beats Evofem Biosciences on 10 of the 16 factors compared between the two stocks.

How does Evofem Biosciences compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

In the previous week, Akari Therapeutics had 13 more articles in the media than Evofem Biosciences. MarketBeat recorded 13 mentions for Akari Therapeutics and 0 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.00 beat Akari Therapeutics' score of -0.13 indicating that Evofem Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Akari Therapeutics	Neutral
Evofem Biosciences	Neutral

Akari Therapeutics currently has a consensus target price of $89.00, indicating a potential upside of 387.14%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akari Therapeutics is more favorable than Evofem Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Evofem Biosciences has higher revenue and earnings than Akari Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.07	N/A

Akari Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.32, indicating that its stock price is 232% less volatile than the broader market.

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 30.7% of Akari Therapeutics shares are owned by insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Akari Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-123.29%	-63.01%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Summary

Akari Therapeutics beats Evofem Biosciences on 8 of the 13 factors compared between the two stocks.

How does Evofem Biosciences compare to IO Biotech?

Evofem Biosciences (NASDAQ:EVFM) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

IO Biotech has a consensus price target of $3.50, indicating a potential upside of 7,191.67%. Given IO Biotech's stronger consensus rating and higher possible upside, analysts clearly believe IO Biotech is more favorable than Evofem Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
IO Biotech	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

IO Biotech has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat IO Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
IO Biotech	N/A	-517.22%	-200.69%

Evofem Biosciences has higher revenue and earnings than IO Biotech. Evofem Biosciences is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.07	N/A
IO Biotech	N/A	N/A	-$95.49M	-$1.35	N/A

In the previous week, Evofem Biosciences' average media sentiment score of 0.00 equaled IO Biotech'saverage media sentiment score.

Company	Overall Sentiment
Evofem Biosciences	Neutral
IO Biotech	Neutral

Evofem Biosciences has a beta of -1.32, suggesting that its share price is 232% less volatile than the broader market. Comparatively, IO Biotech has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 54.8% of IO Biotech shares are owned by institutional investors. 0.0% of Evofem Biosciences shares are owned by company insiders. Comparatively, 2.3% of IO Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Evofem Biosciences and IO Biotech tied by winning 6 of the 12 factors compared between the two stocks.

Get Evofem Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVFM vs. The Competition

Export

Metric	Evofem Biosciences	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$981K	$927.43M	$6.46B	$12.34B
Dividend Yield	N/A	4.84%	2.76%	5.28%
P/E Ratio	-0.01	1.46	21.00	25.66
Price / Sales	0.09	119.63	562.18	86.31
Price / Cash	N/A	20.07	43.49	56.67
Price / Book	0.00	7.59	10.41	7.14
Net Income	$52.98M	-$3.64M	$3.57B	$335.98M
7 Day Performance	N/A	3.01%	6.40%	4.11%
1 Month Performance	N/A	76.62%	3.54%	2.52%
1 Year Performance	N/A	126.61%	34.14%	35.04%

Evofem Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVFM Evofem Biosciences	N/A	$0.01 flat	N/A	-25.3%	$981K	$11.39M	N/A	120	Gap Down High Trading Volume
INDP Indaptus Therapeutics	0.3288 of 5 stars	$1.75 +1.2%	N/A	-88.2%	$3.92M	N/A	N/A	6	Gap Down
GOVX GeoVax Labs	2.9334 of 5 stars	$1.30 -5.1%	$150.00 +11,438.5%	-85.6%	$3.76M	$2.49M	N/A	10	Gap Up
SNGX Soligenix	2.1196 of 5 stars	$0.36 +17.1%	$6.00 +1,553.8%	-78.4%	$3.74M	N/A	N/A	20	Positive News Gap Up High Trading Volume
AKTX Akari Therapeutics	2.481 of 5 stars	$3.15 +2.9%	$89.00 +2,725.4%	-64.2%	$3.59M	N/A	N/A	9	Earnings Report Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVFM) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evofem Biosciences (EVFM) Competitors

EVFM vs. INDP, GOVX, SNGX, AKTX, and IOBT

How does Evofem Biosciences compare to Indaptus Therapeutics?

Summary

How does Evofem Biosciences compare to GeoVax Labs?

Summary

How does Evofem Biosciences compare to Soligenix?

Summary

How does Evofem Biosciences compare to Akari Therapeutics?

Summary

How does Evofem Biosciences compare to IO Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVFM vs. The Competition

Evofem Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evofem Biosciences (EVFM) Competitors

EVFM vs. INDP, GOVX, SNGX, AKTX, and IOBT

How does Evofem Biosciences compare to Indaptus Therapeutics?

Which has more risk and volatility, EVFM or INDP?

Does the media favor EVFM or INDP?

Do analysts recommend EVFM or INDP?

Which has better valuation and earnings, EVFM or INDP?

Is EVFM or INDP more profitable?

Do insiders & institutionals believe in EVFM or INDP?

Summary

How does Evofem Biosciences compare to GeoVax Labs?

Which has more volatility & risk, EVFM or GOVX?

Which has stronger valuation and earnings, EVFM or GOVX?

Is EVFM or GOVX more profitable?

Do analysts rate EVFM or GOVX?

Do institutionals and insiders have more ownership in EVFM or GOVX?

Does the media favor EVFM or GOVX?

Summary

How does Evofem Biosciences compare to Soligenix?

Which has more volatility & risk, SNGX or EVFM?

Does the media prefer SNGX or EVFM?

Do institutionals & insiders hold more shares of SNGX or EVFM?

Do analysts recommend SNGX or EVFM?

Which has better valuation & earnings, SNGX or EVFM?

Is SNGX or EVFM more profitable?

Summary

How does Evofem Biosciences compare to Akari Therapeutics?

Does the media refer more to AKTX or EVFM?

Do analysts prefer AKTX or EVFM?

Which has stronger valuation and earnings, AKTX or EVFM?

Which has more risk and volatility, AKTX or EVFM?

Do insiders & institutionals believe in AKTX or EVFM?

Is AKTX or EVFM more profitable?

Summary

How does Evofem Biosciences compare to IO Biotech?

Do analysts rate EVFM or IOBT?

Is EVFM or IOBT more profitable?

Which has stronger valuation & earnings, EVFM or IOBT?

Does the media refer more to EVFM or IOBT?

Which has more volatility & risk, EVFM or IOBT?

Do insiders and institutionals believe in EVFM or IOBT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVFM vs. The Competition

Evofem Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools